Killing of *Pseudomonas aeruginosa* by Chicken Cathelicidin-2 Is Immunogenically Silent, Preventing Lung Inflammation *In Vivo*

Maarten Coorens,a Brandon J. H. Banaschewski,b Brandon J. Baer,b Cory Yamashita,b Albert van Dijk,a Henk P. Haagsman,a Ruud A. W. Veldhuizen,b Edwin J. A. Veldhuizena

Department of Infectious Diseases and Immunology, Division of Molecular Host Defence, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands; Department of Physiology and Pharmacology, the University of Western Ontario, London, Ontario, Canada

**ABSTRACT** The development of antibiotic resistance by *Pseudomonas aeruginosa* is a major concern in the treatment of bacterial pneumonia. In the search for novel anti-infective therapies, the chicken-derived peptide cathelicidin-2 (CATH-2) has emerged as a potential candidate, with strong broad-spectrum antimicrobial activity and the ability to limit inflammation by inhibiting Toll-like receptor 2 (TLR2) and TLR4 activation. However, as it is unknown how CATH-2 affects inflammation *in vivo*, we investigated how CATH-2-mediated killing of *P. aeruginosa* affects lung inflammation in a murine model. First, murine macrophages were used to determine whether CATH-2-mediated killing of *P. aeruginosa* reduced proinflammatory cytokine production *in vitro*. Next, a murine lung model was used to analyze how CATH-2-mediated killing of *P. aeruginosa* affects neutrophil and macrophage recruitment as well as cytokine/chemokine production in the lung. Our results show that CATH-2 kills *P. aeruginosa* in an immunogenically silent manner both *in vitro* and *in vivo*. Treatment with CATH-2-killed *P. aeruginosa* showed reduced neutrophil recruitment to the lung as well as inhibition of cytokine and chemokine production, compared to treatment with heat- or gentamicin-killed bacteria. Together, these results show the potential for CATH-2 as a dual-activity antibiotic in bacterial pneumonia, which can both kill *P. aeruginosa* and prevent excessive inflammation.

**KEYWORDS** innate immunity, cathelicidin, host defense peptide, immunomodulation, alternative to antibiotics

*Pseudomonas aeruginosa* is a Gram-negative bacterium which can cause opportunistic infections in the lungs of susceptible patients (1–3). Chronic *P. aeruginosa* infections are commonly associated with cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD), and effective treatment is difficult due to the development of multidrug resistance (MDR) in these bacteria (4–6). Adding to the complexity of the pathophysiology of the infected CF and COPD patients is the presence of chronic inflammation within the lung (7, 8). This chronic inflammation is characterized by high neutrophil numbers and the release of proinflammatory mediators, which are insufficient to clear the infection. The tissue damage and lung dysfunction associated with chronic infection are ultimately the most common cause of death in these patients (9–11).

Research into novel therapeutics for the treatment of *P. aeruginosa* infections has shown that cathelicidins are a promising alternative to conventional antibiotics (12–15). Cathelicidins are short cationic peptides with broad-spectrum antimicrobial activity...
against various pathogens, including Gram-positive and Gram-negative bacteria (16, 17). This broad-spectrum antimicrobial activity has also been observed for chicken cathelicidin-2 (CATH-2) and includes activity against MDR *P. aeruginosa* strains (15). In addition, unlike most other cathelicidins, CATH-2 has been shown to retain antimicrobial activity under physiological conditions (18). Importantly, we recently showed that CATH-2 has a dual function, with regard to both killing Gram-negative bacteria and subsequently inhibiting the inflammatory response against the killed microbe (19). This “silent killing” was demonstrated against *Escherichia coli* and *Salmonella enterica* serovar Enteritidis, where CATH-2 neutralizes lipopolysaccharide (LPS) and lipoproteins released from the bacterial outer membrane, which prevents Toll-like receptor 2 (TLR2) and TLR4 activation on macrophages. However, it is unknown whether CATH-2 is able to silently kill other clinically relevant Gram-negatives, such as *P. aeruginosa*, and whether this reduced inflammation is also observed in an *in vivo* situation.

This study tests the hypothesis that CATH-2 mediates silent killing of *P. aeruginosa* both in vitro and in vivo. To test silent killing in vitro, tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) release by murine macrophages was determined after stimulation with CATH-2-killed *P. aeruginosa* and was compared to release after stimulation with viable, heat-killed, and gentamicin-killed *P. aeruginosa*. Subsequently, the *in vivo* effect of CATH-2-killed *P. aeruginosa* on leukocyte recruitment and release of cytokines in the bronchoalveolar lavage fluid (BALF) was determined after intratracheal instillation in mice. Overall, this study demonstrates CATH-2-mediated silent killing of *P. aeruginosa* in both in vitro and in vivo settings and underlines the potential therapeutic value of CATH-2-based anti-infectives.

**RESULTS**

**CATH-2 inhibits *P. aeruginosa*-induced macrophage activation.** To determine the antimicrobial activity of CATH-2 against *P. aeruginosa* under physiological cell culture conditions, a colony counting assay was performed in Dulbecco modified Eagle medium (DMEM) plus 10% fetal calf serum (FCS) (Fig. 1A). The activity of CATH-2 was compared to that of the human antimicrobial peptide LL-37 and equine CATH-1 (eCATH-1). A 5 μM concentration of CATH-2 completely killed 3 × 10^5 to 3 × 10^6 CFU/ml *P. aeruginosa* and decreased *P. aeruginosa* viability 1,000-fold at 3 × 10^7 CFU/ml. In contrast, LL-37 and eCATH-1 did not show any antimicrobial activity. To determine whether CATH-2-mediated killing resulted in reduced macrophage activation by *P. aeruginosa*, J774.A1 murine macrophages were stimulated with viable *P. aeruginosa* in combination with 5 μM CATH-2, LL-37, or eCATH-1, after which TNF-α production (Fig. 1B) and IL-6 production (Fig. 1C) were determined after 2 h and 24 h, respectively. CATH-2 significantly reduced *P. aeruginosa*-induced TNF-α and IL-6 production, in contrast to LL-37 and eCATH-1, which did not affect cytokine production.

**CATH-2 silently kills *P. aeruginosa**. To determine the effect of bacterial killing on macrophage activation, *P. aeruginosa* either was left untreated or was heat killed, gentamicin killed, or CATH-2 killed (Fig. 2A). Subsequently, J774.A1 macrophages were stimulated for 2 h, after which TNF-α release was determined (Fig. 2B). Live and gentamicin-killed bacteria induced similar levels of TNF-α release at 3 × 10^6 CFU/ml, while live *P. aeruginosa* is more potent at 3 × 10^7 CFU/ml than gentamicin-killed bacteria. Heat-killed *P. aeruginosa* did not induce TNF-α release below 3 × 10^6 CFU/ml, while CATH-2-mediated killing almost completely inhibited TNF-α release at all bacterial concentrations, indicating that CATH-2-mediated killing of *P. aeruginosa* is immunologically silent. Because both CATH-2 and LL-37 were previously shown to inhibit the activation of macrophages by nonviable *E. coli* (19), macrophages were also stimulated with gentamicin-treated bacteria (250 μg/ml) in combination with CATH-2, LL-37, or eCATH-1, after which TNF-α production was measured (Fig. 3A). Similar to the previously described results with *E. coli*, both CATH-2 and LL-37 were able to inhibit macrophage activation by gentamicin-treated *P. aeruginosa*, while eCATH-1 did not affect activation. Furthermore, to determine whether the inhibition is related to the inhibition of TLR activation, J774.A1 macrophages were stimulated with the known
P. aeruginosa-derived TLR ligands LPS (Fig. 3B) and flagellin (Fig. 3C) in the presence of 5 μM CATH-2 or LL-37. While LPS-induced TNF-α production was potently inhibited by both CATH-2 and LL-37, flagellin-induced activation was unaffected by either peptide.

CATH-2 inhibits P. aeruginosa-induced PMN recruitment in vivo. The results described above show that CATH-2 is able to inhibit in vitro macrophage activation against P. aeruginosa; however, it is unknown whether this inhibitory effect is maintained in an in vivo setting. To determine whether this is the case, heat-killed, gentamicin-killed, or CATH-2-killed P. aeruginosa (2 × 10^6 CFU/ml) was instilled in mouse lungs for 6 h, after which lung function was assessed and leukocyte numbers, cytokine/chemokine release, and total protein content were determined in BALF. Lung compliance and elastance were determined to assess whether the different experimental conditions would affect lung function; however, no significant changes were observed (Table 1). Analysis of total cell numbers in the BALF showed that the killing of P. aeruginosa by gentamicin resulted in the highest cell count (Fig. 4A). Treatment with
heat-killed bacteria also increased cell numbers in the BALF, albeit not significantly, and no change in total cell numbers was observed in animals after treatment with CATH-2-killed *P. aeruginosa*, in comparison to naive animals. In both the heat-killed and gentamicin-killed treatment groups, polymorphonuclear cells (PMNs) were the main cell type in BALF, while macrophages remained the largest portion of cells in the naive mice and mice treated with CATH-2-killed bacteria (Fig. 4B and C), although mice treated with CATH-2-killed bacteria did show a nonsignificant increase in PMNs compared to the naive mice (PMN counts: naive, 0.09 ± 0.04 cells/ml; CATH-2 treated, 0.68 ± 0.75 cells/ml; heat treated, 7.41 ± 3.10 cells/ml; gentamicin treated, 18.85 ± 6.63 × 10^4 cells/ml). In addition, the number of PMNs in the treatment groups correlated with the higher matrix metalloproteinase 9 (MMP-9) levels measured in the BALF (Fig. 4D), which has previously been linked to PMN influx (20). Furthermore, no changes in the BALF protein content were detected after treatment with CATH-2-killed, heat-killed, or gentamicin-killed bacteria, although there was a tendency toward higher protein levels in the group that received CATH-2-killed bacteria (Table 1).

**CATH-2 inhibits *P. aeruginosa*-induced cytokine and chemokine secretion in vivo.** To further examine the extent of inflammation in the lung, multiplex analysis was performed on various pro- and anti-inflammatory cytokines, as well as various chemokines. Both heat-killed and gentamicin-killed bacteria induced the release of proinflammatory cytokines TNF-α (Fig. 5A) and IL-6 (Fig. 5B), while gentamicin-killed bacteria also significantly induced the release of IL-23p19 (Fig. 5C) and IL-12p70 (Fig. 5D) into the BALF. Treatment with CATH-2-killed bacteria resulted in significantly lower concentrations of TNF-α, IL-6, IL-23p19, and IL-12p70 than did treatment with gentamicin-killed bacteria and did not induce a significant increase in these cytokines compared to those in naive mice (Fig. 5A to D). Similar induction patterns were observed for granulocyte colony-stimulating factor (G-CSF) (Fig. 5E), keratinocyte chemoattractant (KC) (Fig. 5F), and macrophage inflammatory protein 2 (MIP-2) (Fig. 5G), with gentamicin-killed *P. aeruginosa* being the strongest inducer of cytokine release, followed by heat-killed
Treatment with CATH-2-killed P. aeruginosa resulted in values close to those obtained for naive mice, and these values were significantly lower than the cytokine release induced by treatment with gentamicin-killed P. aeruginosa. Furthermore, IL-33 was significantly increased only in the gentamicin-killed treatment group (Fig. 5H). Levels of IL-1β, IL-4, IL-10, and monocyte chemoattractant protein 1 (MCP-1) remained low and did not show any significant changes (data not shown).

**CATH-2 inhibits inflammation induced by P. aeruginosa killed by gentamicin in vivo.** To further explore the anti-inflammatory effects of CATH-2 that are independent
of its killing activity, CATH-2, LL-37, or porcine myeloid antimicrobial peptide-23 (PMAP-23) was added to gentamicin-killed bacteria and instilled into the mouse lung. Six hours following the instillation, lung lavages were performed and the BALF was analyzed for differential cell counts and for three of the inflammatory mediators, TNF-α, IL-6, and KC, that showed a marked response in the previous experiment (Fig. 5). Compared to control (gentamicin-instilled) animals, animals receiving gentamicin-killed P. aeruginosa had a significant inflammatory response, as indicated by a large increase in the total cell count, percentage of neutrophils, and the concentrations of the three inflammatory cytokines in the lavage fluid (Fig. 6A to F). Treatment with gentamicin-killed P. aeruginosa that was supplemented with 20 μM CATH-2 or LL-37 resulted in a significantly reduced total cell count and percentage of neutrophils, and this was associated with significantly lower concentrations of TNF-α, IL-6, and KC (Fig. 6A to F).

TABLE 1 Effect of CATH-2 treatment on lung function

| Treatment | Lung compliance (ml/cm H2O × 10³) | Lung elastance (cm H2O/ml) | Protein content (mg/kg BW) |
|-----------|-----------------------------------|-----------------------------|---------------------------|
| Control   | 57.8 ± 7.0                        | 17.5 ± 2.2                  | 14.05 ± 1.8               |
| CATH-2    | 52.9 ± 9.2                        | 19.4 ± 3.6                  | 21.6 ± 9.1                |
| Heat      | 55.6 ± 8.0                        | 18.3 ± 2.9                  | 14.45 ± 3.1               |
| Gentamicin| 58.9 ± 8.7                        | 17.3 ± 2.6                  | 15.75 ± 6.2               |

*Male C57BL/6 mice were instilled with 50 μl of 2 × 10⁶ CFU/ml P. aeruginosa, which was either CATH-2 killed (20 μM), gentamicin killed (1 mg/ml), or heat killed (90°C, 1 h). Alternatively, control mice were instilled with an air bolus. After 6 h, lung compliance was determined and lung elastance was calculated. In addition, total protein levels in the BALF were determined. n = 3 or more. Statistical analysis was performed by one-way ANOVA with Bonferroni’s post hoc test, but no significant differences were detected.

FIG 4 CATH-2-mediated killing prevents in vivo lung inflammation. Male C57BL/6 mice were intratracheally instilled with 50 μl of 2 × 10⁶ CFU/ml P. aeruginosa, which was either CATH-2 killed (20 μM), gentamicin killed (1 mg/ml), or heat killed (90°C, 1 h). Alternatively, control mice were instilled with an air bolus. After 6 h, total cell counts in BALF (A), as well as macrophage (B) and PMN (C) percentages, were determined by differential cell count. In addition, MMP-9 concentrations in BALF (D) were determined. n = 5 or more. Error bars = SEM. Statistical differences were determined by one-way ANOVA with Bonferroni’s post hoc test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
non-LPS binding peptide PMAP-23 resulted in an intermediate response for each of the outcomes (Fig. 6A to F).

**DISCUSSION**

CATH-2 has previously been shown to cause "silent killing," i.e., to kill bacteria in a nonimmunogenic manner (19). The current study provides evidence that silent killing by CATH-2 in vitro is not restricted to *E. coli* and also occurs against *P. aeruginosa*, a clinically relevant lung pathogen. In addition, our results provide evidence that CATH-2-mediated killing of *P. aeruginosa* inhibits pulmonary inflammation in a mouse lung model by reducing PMN recruitment and preventing the release of proinflammatory cytokines and chemokines. Based on these data, it is concluded that CATH-2 kills Gram-negative bacteria in an immunogenically silent manner, limiting inflammation both in vitro and in vivo.

While CATH-2 potently inhibits *P. aeruginosa*-induced macrophage activation, it also strongly inhibits TLR4 activation by *P. aeruginosa* LPS. This is in line with a previous study, which shows that silent killing of *E. coli* by CATH-2 is a two-step process in which CATH-2 first kills *E. coli* and then subsequently neutralizes LPS from the bacterial outer membrane to inhibit TLR4 activation (19, 21). In contrast, killing of *P. aeruginosa* by gentamicin, a clinically relevant antibiotic for pneumonia, or, alternatively, by heat treatment was not sufficient to prevent an inflammatory response. For *E. coli*, it was shown that these methods cause very different morphological changes in *E. coli* with subsequent differing levels of release of bacterial products (mainly LPS for Gram-negative bacteria), which can lead to an immune response (19), as observed for *P. aeruginosa* in the current study. Our results also show that while LL-37 is unable to kill *P. aeruginosa* under cell culture conditions, it can inhibit macrophage activation by
gentamicin-treated *P. aeruginosa* and inhibit TLR4 activation by *P. aeruginosa* LPS, since the non-LPS binding peptide eCATH-1 did not possess this activity (Fig. 3A and B). This corresponds to the previously reported lack of antimicrobial activity of LL-37 against *E. coli* under cell culture conditions and the inhibition of macrophage activation by LL-37 in the context of nonviable *E. coli* only (19, 22). Together, this strongly suggests that both CATH-2 and LL-37 inhibit *P. aeruginosa*- and *E. coli*-induced macrophage activation through similar mechanisms but that only CATH-2 has the dual function of killing Gram-negatives under physiological cell culture conditions and subsequently inhibiting macrophage activation.

Notably, these *in vitro* observations were recapitulated in the *in vivo* studies. Whereas the *in vitro* environment provides strong evidence for the role of CATH-2 in limiting macrophage inflammation in the presence of bacterial products, an *in vivo* environment is more complex, as inflammation will involve multiple cell types, cell migration, and a physiological local milieu that may vary between different airways and alveoli. Despite this complexity, *in vivo* administration of CATH-2-killed *P. aeruginosa* resulted in significantly less inflammation, including reduced neutrophil infiltration and lower concentrations of various inflammatory cytokines, compared to that of heat- or gentamicin-killed bacteria. Further, LL-37 was also able to downregulate inflammation *in vivo* when added to gentamicin-killed bacteria. Based on the *in vitro* observations,
the mechanism for these effects of both CATH-2 and LL-37 is through limiting TLR4 activation; however, other mechanisms cannot be excluded, specifically since PMAP-23, which lacks LPS binding capability, still reduced inflammation, although to a lesser extent than the other two peptides. Overall, these observations provide evidence for an important role of cathelicidins in mitigating inflammation due to bacterial products that are released when bacteria are killed in vivo.

Clinically, the anti-inflammatory effect of CATH-2 on TLR4 activation may have a strong potential benefit for the development of cathelicidin-based anti-infective therapies for CF patients. In these patients, TLR4-mediated immune activation has been shown to play an important role in inflammation during P. aeruginosa infections. This is partially caused by adaptations of P. aeruginosa to the environment of CF patients’ lungs. It has been shown that P. aeruginosa modifies its LPS from a penta- to a hexa-acylated form, which is more potent in the activation of TLR4 (4, 23–25). In addition, regulation of immune activation, including TLR4 activation in alveolar macrophages and epithelial cells, appears to be dysregulated in CF patients, in part due to the lack of a functional cystic fibrosis transmembrane conductance regulator (CFTR) (26–28). This dysregulation includes the lack of proper TLR4 degradation in lysosomal compartments (29), as well as a lack of negative feedback upon TLR4 activation (30–32), which ultimately causes a higher inflammatory response in the lungs of CF patients. Since CATH-2 has a dual function of both killing P. aeruginosa and inhibiting TLR4 activation, treatment of P. aeruginosa infections in CF patients with CATH-2 (or CATH-2-derived compounds) can potentially reduce bacterial numbers and limit inflammation in the lung.

Another important characteristic of CATH-2 for anti-infective drug development is its antimicrobial activity under complex conditions, which includes solutions containing salt and serum components or bovine lipid extract surfactant (18, 33). Furthermore, CATH-2 has broad-spectrum antimicrobial activity, which includes activity against MDR P. aeruginosa (15) as well as activity against Staphylococcus aureus, which is another common infectious pathogen in CF patients (34). While no proof of silent killing of Gram-positives, such as S. aureus, is yet available, CATH-2 has been shown to inhibit macrophage TLR2 activation by S. aureus-derived lipoteichoic acid (19), suggesting that silent killing might not be restricted to Gram-negatives.

While our study has focused on the ability of CATH-2 to both kill bacteria and mitigate inflammation, other cathelicidins may also have potential beneficial functions in the treatment of lung infections. Our experiments suggest that LL-37 may have benefits as an anti-inflammatory agent that can be combined with antibiotics. In addition, while LL-37 is unable to directly kill P. aeruginosa under physiological conditions, a recent report showed that LL-37 can lower P. aeruginosa bacterial loads in a murine lung model, which appeared to be the result of increased PMN influx in the lung (35). This indicates that indirect effects can also play an important role in cathelicidin-mediated bacterial clearance from the lung and that different cathelicidins might depend on different functionalities to improve the outcome of infections. Furthermore, CATH-2-derived peptides, as well as other cathelicidins, have been shown to exert anti-biofilm activity, which could be important in the context of biofilm formation in CF patients (36–38). However, further research is needed to determine if these beneficial properties of cathelicidins can be translated into effective therapies for pneumonia and other infections. Specifically related to our study, future studies should examine the silent killing and potential other effects of CATH-2 in the context of an in vivo P. aeruginosa infection under CF-like conditions.

As with all studies, our experiments are associated with some limitations. For example, our in vivo studies were limited to studying anti-inflammatory effects due to bacterial products of killed bacteria. The advantage of this approach was to solely assess the anti-inflammatory effects of the peptides independent of their bactericidal activities; the ability of CATH-2, and potentially other peptides, to both kill bacteria and mitigate inflammation in vivo requires further study. In addition, a minor limitation, due to logistical issues, was that the in vitro experiments utilized eCATH1, but the in vivo
study used PMAP-23, as a non-LPS binding peptide. However, it should be noted that both of these peptides have been extensively characterized with regard to their activities (18).

Overall, our results provide evidence for the silent killing of a relevant lung pathogen by CATH-2. While silent killing by CATH-2 has been observed against E. coli and Salmonella Enteritidis in vitro, this is the first study that shows that CATH-2-mediated killing of P. aeruginosa leads to inhibition of inflammation in vivo as well as in vitro. Together with previous reports, these results underline the potential for CATH-2 as a template for the development of an anti-infective therapy, for instance for CF patients, with both antimicrobial and anti-inflammatory functions.

MATERIALS AND METHODS

Reagents. P. aeruginosa LPS was obtained from Sigma-Aldrich (St. Louis, MO, USA), and P. aeruginosa flagellin was obtained from Invivogen (Toulouse, France). Chicken CATH-2, human LL-37, and porcine myeloid antimicrobial peptide-23, (PMAP-23) were synthesized by Fmoc (9-fluorenylmethoxy carbonyl) chemistry at China Peptides (CPC Scientific, Sunnyvale, CA, USA), and equine CATH-1 was synthesized by Fmoc chemistry at the Academic Centre for Dentistry Amsterdam (Amsterdam, the Netherlands). Gentamicin solution was obtained from Sigma-Aldrich.

Bacterial culture. For in vitro experiments, P. aeruginosa ATCC 27853 (ATCC, Manassas, VA, USA) was grown to log phase in Luria broth (BioTRADING Benelux B.V., Mijdrecht, the Netherlands). After measurement of the optical density (OD), bacteria were centrifuged at 1,200 \( \times g \) for 10 min and diluted in DMEM (Thermo Fisher Scientific, Waltham, MA, USA). To prepare killed bacteria, bacteria were incubated for 1 h at 90°C (heat killed), 1 h with 1 mg/ml gentamicin at 37°C (gentamicin killed), or 1 h with 20 \( \mu M \) CATH-2 at 37°C (CATH-2 killed).

Cell culture. I77A1 murine macrophages were a kind gift of Jos van Putten (Division of Infection Biology, Department of Infectious Diseases and Immunology, Utrecht University, the Netherlands). Cells were cultured in DMEM supplemented with 10% FCS (Bodinco B.V., Alkmaar, the Netherlands). Cells were seeded in 96-well plates (7.5 \( \times \) 10\(^4\) cells/well) for adherence overnight. Cells were subsequently stimulated with live, heat-killed, gentamicin-killed, or CATH-2-killed bacteria in the presence or absence of other cathelicids. After 2 h of stimulation, TNF-\( \alpha \) concentrations were determined in the supernatant. Alternatively, to determine IL-6 concentrations in the supernatant, cells were washed three times after 2 h of incubation, followed by an additional 22 h of incubation in the presence of 250 \( \mu g/ml \) gentamicin.

ELISA. ELISA DuoSets for mouse TNF-\( \alpha \) and mouse IL-6 were obtained from R&D Systems (Minneapolis, MN, USA). Samples were diluted in phosphate-buffered saline (PBS) with 1% bovine serum albumin (BSA), pH 7.4, before analysis. ELISAs were performed according to the manufacturer’s protocol. For ELISA plate analysis, absorbance was determined at an OD at 450 nm (OD\(_{450}\)) and was corrected at OD\(_{650}\). Absorbance was determined with a FLUOstar Omega microplate reader (BMG Labtech GmbH, Ortenberg, Germany) and analyzed with MARS data analysis software (BMG Labtech GmbH).

Colony counting assay. Colony counting assays were performed after coincubation of P. aeruginosa with cathelicidins in 20-\( \mu l \) volumes at 37°C for 2 h in round-bottom polypropylene 96-well plates. After incubation, samples were diluted with 180 \( \mu l \), which was followed by spread-plating 10-fold dilutions in PBS on tryptic soy agar (TSA) plates (Oxoid Limited, Hampshire, United Kingdom). Plates were incubated overnight at 37°C, after which CFU counts were determined, with a detection limit of 10\(^2\) CFU/ml.

Preparation of killed bacteria for in vivo analysis. An overnight culture of P. aeruginosa ATCC 27853 was diluted 10-fold in tryptic soy broth (TSB). The optical density was measured, and bacteria were further diluted in sterile saline to approximately 2 \( \times \) 10\(^8\) CFU/ml. Subsequently, the bacteria were killed by CATH-2, heat, or gentamicin as described above and immediately used without any additional wash steps for intratracheal instillation. Part of the bacterial solution was plated via spot plating on TSA and incubated overnight at 37°C to ensure complete bacterial killing. For our second in vivo experiment, a similar procedure was utilized except that the bacteria were killed by incubation with a lower dose of gentamicin (4 \( \mu g/ml \)).

Administration of killed bacteria in vivo. Male C57BL/6 mice (Charles River, Sherbrooke, Quebec, Canada), weighing 25 to 32 g, were used for this experiment. All animal procedures were approved by the Animal Use Subcommittee at the University of Western Ontario and followed the approved guidelines described by the Canadian Council of Animal Care. Mice were anesthetized by intraperitoneal (i.p.) injection of ketamine (130 mg/kg body weight [BW]) and dexametomidine (0.5 mg/kg BW) and then intubated using a 20-gauge catheter, with the aid of a fiber optic stylet (BioLite intubation system for small rodents; BioTex, Inc., Houston, TX, USA). Once intubated, the mice were randomized to instillation with 50 \( \mu l \) of heat-, gentamicin-, or CATH-2-killed bacterial preparations (see above) or were instilled with an air bolus (naive controls). Animals were randomized to a specific administration, and experiments were performed on 3 or 4 mice per day (different treatment groups on the same day). Animals were housed individually after intratracheal instillation, and individual mice were used for the statistics. Mice were extubated following successful instillation and subsequently injected with a reversal agent for dexmedetomidine, atipamezole (Antisedan), and allowed to breathe spontaneously for the following 6 h. After 6 h, the mice were euthanized by i.p. injection of sodium pentobarbital and dissection of the descending aorta. The animals were placed on a FlexiVent system to measure lung compliance and elastance. Following these measurements, whole-lung lavage fluid was collected by
using three 1-ml aliquots of sterile saline. The whole-lung lavage fluid was immediately centrifuged at $150 \times g$ for 10 min, and the pellet was collected for cell analysis, while the supernatant was collected to measure protein content and cytokine concentrations. Differential cell analysis of the cells obtained in the lavage fluid was done as previously described (39). Protein content of the lavage fluid was measured using a Micro BCA protein assay kit (Pierce, Rockford, IL, USA), according to the manufacturer's instructions. Levels of mouse cytokines were measured using multiplexed immunoassay kits according to the manufacturer's instructions (R&D Systems, Minneapolis, MN). A Bio-Plex 200 readout system (Bio-Rad) was used, which utilizes Luminex xMAP fluorescent bead-based technology (Luminex Corporation, Austin, TX). Cytokine levels were automatically calculated from standard curves using Bio-Plex Manager software (v.4.1.1, Bio-Rad).

In a second experiment, similar procedures were utilized; however, intubated mice were randomized to receive 50 μl of gentamicin-killed bacterial preparations without or with supplementation with 20 μM CATH-2, LL-37, or PMAP-23. A group of mice receiving 50 μl of gentamicin (4 μg/ml in saline) was used as a control group. Six hours following intubation, the mice were euthanized and lung lavage was performed as described above. Differential cell analysis of the cells obtained in the lavage fluid was done as previously described above. The levels of mouse IL-6, KC, and TNF-α were measured using ELISA kits per the manufacturer's instructions (R&D Systems, Minneapolis, MN). A Bio-Plex 200 readout system was used (Bio-Rad), and cytokine levels were automatically calculated from standard curves using Bio-Plex Manager software (v.4.1.1, Bio-Rad).

ACKNOWLEDGMENTS

We thank Lynda McCaig for her excellent technical assistance in the in vivo experiments.

This work was supported by the Immuno Valley ALTernatives to ANTibiotics (ALTANT) Animal Specific Immuno-modulatory Antimicrobials (ASIA) 2 program of the Dutch Ministry of Economic Affairs (M.C., A.V.D., H.P.H., E.J.A.V.) and the Human Frontier Science program (H.P.H.; RGP0016/2009-C). R.A.W.V., C.Y., and B.J.H.B. are supported by the Canadian Institutes of Health Research (FRN-114936), the Cystic Fibrosis Canada Foundation, and the Ontario Graduate Studentship, respectively.

The funders had no role in the study design, data collection and interpretation, or the decision to submit the work for publication.

M.C., B.J.H.B., B.J.B., and A.V.D. contributed to the experimentation, M.C., H.P.H., R.A.W.V., and E.J.A.V. contributed to the research design, M.C., B.J.H.B., B.J.B., and C.Y. contributed to the data analysis, and M.C., C.Y., H.P.H., R.A.W.V., and E.J.A.V. contributed to the manuscript preparation.

REFERENCES

1. Lyczak JB, Cannon CL, Pier GB. 2000. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect 2:1051–1060. https://doi.org/10.1016/S1286-4579(00)01259-4.
2. Planteau B, Perret D, Dubuisson E, Roujandy A, Laurent V, Le Monnier A, Legriel S, Ferre A, Bruneel F, Chiles PG, Bedos PJ. 2015. Antibiotics against Pseudomonas aeruginosa for COPD exacerbation in ICU: a 10-year retrospective study. Int J Chron Obstruct Pulmon Dis 10:379–388. https://doi.org/10.2147/COPD.S71413.
3. Sousa D, Justo I, Domínguez A, Izquierdo C, Ruiz L, Nebot M, Bayas JM, Celorio JM, Varona W, Llinares P, Míguez E, Sanchez E, Carratala J. 2013. Community-acquired pneumonia in immunocompromised older patients: incidence, causalising organisms and outcome. Clin Microbiol Infect 19:187–192. https://doi.org/10.1111/j.1469-0691.2012.03765.x.
4. Bouvier NM. 2016. Cystic fibrosis and the war for iron at the host-pathogen battlefront. Proc Natl Acad Sci U S A 113:1480–1482. https://doi.org/10.1073/pnas.1521511113.
5. Coughds PD, Li B, Hoogkamp-Korstanje JA, Stobberingh E, Antibiotic Resistance Surveillance Group. 2013. Thirteen years of antibiotic susceptibility surveillance of Pseudomonas aeruginosa from intensive care units and urology services in the Netherlands. Eur J Clin Microbiol Infect Dis 32:283–288. https://doi.org/10.1007/s10096-012-1741-4.
6. Willmann M, Bezdan D, Zapata L, Susak H, Vogel W, Schroppel K, Liese J, Weidenmaier C, Autenrieth IB, Ossowski S, Peter S. 2015. Analysis of a long-term outbreak of XDR Pseudomonas aeruginosa: a molecular epidemiological study. J Antimicrob Chemother 70:1322–1330. https://doi.org/10.1093/acc/dku546.
7. Brusselle GG, Joos GF, Bracke KR. 2011. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 378:1015–1026. https://doi.org/10.1016/S0140-6736(11)60988-4.
8. Folkesson A, Jelsbak L, Yang L, Johansen HK, Ciofu O, Hoiby N, Molin S. 2012. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat Rev Microbiol 10:841–851. https://doi.org/10.1038/nrmicro2907.
9. Cantin AM, Hart D, Konstan MW, Chmiel JF. 2015. Inflammation in cystic fibrosis lung disease: pathogenesis and therapy. J Cyst Fibros 14: 419–430. https://doi.org/10.1016/j.jcf.2015.03.003.
10. Reverri EJ, Morrissey BM, Cross CE, Steinberg FM. 2014. Inflammation, oxidative stress, and cardiovascular disease risk factors in adults with cystic fibrosis. Free Radiol Biol Med 76:261–277. https://doi.org/10.1016/j.freeradbiom.2014.08.005.
11. Hoenders K, Condliffe A. 2013. The neutrophil in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 48:531–539. https://doi.org/10.1165/rcmb.2012-0492TR.
12. Byfield FJ, Kovalski M, Cruz K, Leszczyńska K, Namiot A, Savage PB, Bucki R, Janney PA. 2011. CATHelicidin LL-37 increases lung epithelial cell stiffness, decreases transepithelial permeability, and prevents epithelial invasion by Pseudomonas aeruginosa. J Immunol 187:5640–5649. https://doi.org/10.4049/jimmunol.1102185.
13. Huang LC, Reins RY, Gallo RL, McDermott AM. 2007. Cathelicidin-deficient (Cnlp−/−) mice show increased susceptibility to Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 48:4498–4508. https://doi.org/10.1167/iovs.07-0274.
14. Yim S, Dhawan P, Ragunath C, Christakos S, Diamond G. 2007. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D3). J Cyst Fibros 6:403–410. https://doi.org/10.1016/j.jcf.2007.03.003.
15. Veldhuizen EJA, Brouwer EC, Schneider VAF, Fluit AC. 2013. Chicken cathelicidins display antimicrobial activity against multiresistant bacteria.
without inducing strong resistance. PLoS One 8:e61964. https://doi.org/10.1371/journal.pone.0061964.
16. Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. 1998. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 42:2206–2214.
17. van Dijk A, Molhoek AM, Veldhuizen EJA, Bokhoven JL, Wagendorp E, Bikker FJ, Haagsman HP. 2009. Identification of chicken cathelicidin-2 core elements involved in antibacterial and immunomodulatory activities. Mol Immunol 46:2465–2473. https://doi.org/10.1016/j.molimm.2009.05.019.
18. Coorens M, Scheenstra MR, Veldhuizen EJA, Haagsman HP. 2017. Interspecies cathelicidin comparison reveals divergence in antimicrobial activity, TLR modulation, chemokine induction and regulation of phagocytosis. Sci Rep 7:40874. https://doi.org/10.1038/srep40874.
19. Coorens M, Schneider VAF, de Groot AM, van Dijk A, Meijerink M, Wells JM, Scheenstra MR, Veldhuizen EJA, Haagsman HP. 2017. Cathelicidins inhibit Escherichia coli-induced TLR2 and TLR4 activation in a viability-dependent manner. J Immunol 199:1418–1428. https://doi.org/10.4049/jimmunol.1602164.
20. Corbel M, Theret N, Cault-Maugendre S, Germain N, Lagente V, Clement B, Boichot E. 2001. Repeated endotoxin exposure induces intestinal fibrosis associated with enhanced gelatinase (MMP-2 and MMP-9) activity. Inflamm Res 50:129–135. https://doi.org/10.1007/s000110050736.
21. Schneider VAF, Coorens M, Ordonez SR, Tjerdema-van Bokhoven JL, Posthuma G, van Dijk A, Haagsman HP, Veldhuizen EJA. 2016. Imaging the antimicrobial mechanism(s) of cathelicidin-2. Sci Rep 6:32948. https://doi.org/10.1038/srep32948.
22. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock REW. 2005. Impact of LL-37 on anti-infective immunity. J Leukoc Biol 77:451–459. https://doi.org/10.1002/jlb.0402140.
23. Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SL. 2002. Human Toll-like receptor 4 recognizes host-dependent LPS modifications. Nat Immunol 3:135–144. https://doi.org/10.1038/ni777.
24. Marvig RL, Sommer LM, Molin S, Johansen HK. 2015. Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis. Nat Genet 47:57–64. https://doi.org/10.1038/ng.3148.
25. Ernst RK, Yi EC, Guo L, Lim KB, Bums JL, Hackett M, Miller SL. 1999. Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science 286:1561–1565. https://doi.org/10.1126/science.286.5444.1561.
26. Cohen TS, Prince A. 2012. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 18:509–519. https://doi.org/10.1038/nm.2715.
27. Lubamba BA, Jones LC, O’Neal WK, Boucher RC, Ribeiro CM. 2015. X-box-binding protein 1 and innate immune responses of human cystic fibrosis alveolar macrophages. Am J Respir Crit Care Med 192:1449–1461. https://doi.org/10.1164/rcrm.201504-0657OC.
28. Bruscia EM, Zhang PX, Ferreira E, Caputo C, Emerson JW, Tuck D, Krause DS, Egan ME. 2009. Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator−/− mice. Am J Respir Cell Mol Biol 40:295–304. https://doi.org/10.1165/rcmb.2008-0170OC.
29. Kelly C, Canning P, Buchanan PJ, Williams MT, Brown V, Gruenert DC, Elborn JS, Ennis M, Schock BC. 2013. Toll-like receptor 4 is not targeted to the lysosome in cystic fibrosis airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 304:L371–L382. https://doi.org/10.1152/ajplung.00372.2011.
30. Kelly C, Williams MT, Elborn JS, Ennis M, Schock BC. 2013. Expression of the inflammatory regulator A20 correlates with lung function in patients with cystic fibrosis. J Cyst Fibros 12:411–415. https://doi.org/10.1016/j.jcf.2012.10.009.
31. Zhang PX, Murray TS, Villella VR, Ferrari E, Esposito S, D’Souza A, Raia V, Maiuri L, Krause DS, Egan ME, Bruscia EM. 2013. Reduced caveolin-1 promotes hyperinflammation due to abnormal heme oxygenase-1 localization in lipopolysaccharide-challenged macrophages with dysfunctional cystic fibrosis transmembrane conductance regulator. J Immunol 190:5196–5206. https://doi.org/10.4049/jimmunol.1201607.
32. Chilappagari S, Venkatesan S, Garapati V, Mahavadi P, Munder A, Seu- bert A, Sarode G, Guenther A, Schmeck BT, Tummelier B, Henke MO. 2014. Impaired TLR4 and HIF expression in cystic fibrosis bronchial epithelial cells downregulates hemeoxygenase-1 and alters iron homeostasis in vitro. Am J Physiol Lung Cell Mol Physiol 307:L791–L799. https://doi.org/10.1152/ajplung.00167.2014.
33. Banaschewski BJH, Veldhuizen EJA, Keating E, Haagsman HP, Zuo YY, Yamashitam CM, Veldhuizen RAW. 2015. Antimicrobial and biophysical properties of surfactant supplemented with an antimicrobial peptide for treatment of bacterial pneumonia. Antimicrob Agents Chemother 59:3075–3083. https://doi.org/10.1128/AAC.04937-14.
34. Bauernfeind A, Bertele RM, Harms K, Horl G, Jungwirth R, Petermuller C, Przyklenk B, Weisslein-Pfister C. 1987. Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis. Infection 15:270–277. https://doi.org/10.1007/BF01641437.
35. Beaumont PE, McHugh B, Weyer Findlay E, MacKellar A, Mackenzie KJ, Gallo Govan JR, Simpson AJ, Davidson DJ. 2014. Cathelicidin host defence peptide augments clearance of pulmonary Pseudomonas aeruginosa infection by its influence on neutrophil function in vivo. PLoS One 9:e99029. https://doi.org/10.1371/journal.pone.0099029.
36. Pompolio A, Scocchi M, Pomponio S, Guida F, Di Primio A, Fiscarelli E, Gennaro R, Di Bonaventura G. 2011. Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients. Peptides 32:1807–1814. https://doi.org/10.1016/j.peptides.2011.08.002.
37. Drenkard E, Ausubel FM. 2002. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 416:740–743. https://doi.org/10.1038/416740a.
38. Molhoek EM, van Dijk A, Veldhuizen EJA, Haagsman HP, Bikker FJ. 2011. A cathelicidin-2-derived peptide effectively impairs Staphylococcus epidermidis biofilms. Int J Antimicrob Agents 37:476–479. https://doi.org/10.1016/j.ijantimicag.2010.12.020.
39. Walker MG, Tessollini JM, McCaig L, Yao LJ, Lewis JF, Veldhuizen RAW. 2009. Elevated endogenous surfactant reduces inflammation in an acute lung injury model. Exp Lung Res 35:591–604. https://doi.org/10.1080/01902140902780460.